Larvol Delta - Arsenal-Biosciences-Announces-First-Patient-Dosed-in-Phase-12-Clinical-Trial-of-AB2100-in-Development-as-a-Treatment-for-Clearcell-Renal-Cell-Carcinoma

AB-2100 - ArsenalBio

https://www.businesswire.com/news/home/20240430131934/en/Arsenal-Biosciences-Announces-First-Patient-Dosed-in-Phase-12-Clinical-Trial-of-AB-2100-in-Development-as-a-Treatment-for-Clear-cell-Renal-Cell-Carcinoma

Apr 30, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next